The United Kingdom - The British Generic Manufacturers Association

The BGMA shows the interests of UK based manufacturers and suppliers of generic medicines and promotes the development of the generic medicines corporation in the United Kingdom. We represent the views and interests of our members and corporation generally to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the institutions of the European Union. According to the most recent NHS figures around 750 million items are recommended generically every year. The increase of generic prescriptions, allied with a reduction in the net ingredients costs, means that comprehensive savings to the NHS medicines bill have now passed more than £13.5 billion annually. A key aspect of the strong generics industry in the UK is that it introduces competition to the supply of instruction medicines making drugs more economical0020to the NHS and add to their availability to patients. The BGMA is made up of members of the generic manufacturing industry, who amid them account for more than 90% of the total UK market by volume. The British Generic Manufacturers Association (BGMA) is having launched a forum in conjunction with the MHRA to focus on assuring the manufacturing quality of generic medicines in the UK. The core role of a successful generic medicines manufacturing region is to get the right medicines at the right time to patients to improve quality of life. The Quality Forum is open to full and society members of the BGMA. This work also stimulates the originator sector to continue analysis-based activity which results in new and improved medicines for patients. There are a number of issues, which are important to our members, in which we engage with a range of stakeholders from parliamentary representatives and government departments, through to the European Union.